Aurinia Pharmaceuticals Inc.
CAFinancials
Valuation Metrics
Aurinia Pharmaceuticals Inc.'s Market Cap is $2.08B. At end of 2025 it was $2.14B. Ranked #1914 of 3,116 in US market (top 61%), #708 of 1,472 on NASDAQ (top 48%), #125 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.08B | US#1,914/3,116 Sec#125/265 |
| Revenue | $312M | US#2,414/3,116 Sec#94/265 |
| Net Income | $314M | US#1,064/3,116 Sec#36/265 |
| Total Assets | $792M | US#2,567/3,116 Sec#119/265 |
| Net Assets | $615M | US#2,084/3,116 Sec#93/265 |
| Employees | 128 | US#2,568/3,116 Sec#159/265 |
| Value | ||
| P/E | 6.61x | US#143/3,116 Sec#6/265 |
| P/B | 3.38x | US#1,934/3,116 Sec#111/265 |
| PEG | 0.02x | US#51/3,116 Sec#6/265 |
| P/S | 6.66x | US#2,533/3,116 Sec#97/265 |
| EV/EBITDA | 10.39x | US#970/3,116 Sec#31/265 |
| FCF Yield | 8.36% | US#863/3,116 Sec#27/265 |
| Profitability | ||
| ROE | 51.09% | US#109/3,116 Sec#8/265 |
| ROA | 39.65% | US#19/3,116 Sec#6/265 |
| Op. Margin | 48.39% | US#143/3,116 Sec#7/265 |
| Revenue Growth | 19.76% | US#696/3,116 Sec#75/265 |
| Earnings Growth | 418.03% | US#83/3,116 Sec#5/265 |
| Financial Health | ||
| Debt Ratio | 28.85% | US#318/3,116 Sec#100/265 |
| Total Debt | $60M | US#2,561/3,116 Sec#148/265 |
| FCF | $174M | US#1,459/3,116 Sec#52/265 |
| Cash | $180M | US#1,812/3,116 Sec#121/265 |
| Current Ratio | 5.42x | US#431/3,116 Sec#132/265 |
| Net Debt/EBITDA | -0.63x | US#364/3,116 Sec#23/265 |
| Performance | ||
| 1Y Return | 22.55% | US#662/3,116 Sec#87/265 |
| 1M Return | 1.96% | US#1,302/3,116 Sec#87/265 |
| From 52W High | -16.16% | US#891/3,116 Sec#53/265 |
| 1Y MDD | -21.75% | US#756/3,116 Sec#25/265 |
| Trading | ||
| Volume | 1,573,384 shares | US#1,754/3,116 Sec#177/265 |
| Trading Value | $26M | US#2,160/3,116 Sec#173/265 |
| Per Share | ||
| EPS | $2.44 | US#1,200/3,116 Sec#35/265 |
| BPS | $4.78 | US#2,288/3,116 Sec#131/265 |
Company Info
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.